|
Jul 14
|
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
|
|
Jul 11
|
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
|
|
Jul 11
|
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
|
|
Jun 18
|
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
|
|
Mar 14
|
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
|
|
Feb 20
|
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
|
|
Feb 18
|
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
|
|
Feb 14
|
Cel-Sci: Fiscal Q1 Earnings Snapshot
|
|
Feb 10
|
CVM: Fiscal Year 2024 Results
|
|
Dec 31
|
CEL-SCI Announces Closing of $5 Million Offering
|
|
Dec 30
|
CEL-SCI Announces Pricing of $5 Million Public Offering
|
|
Dec 12
|
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
|
|
Oct 1
|
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
|
|
Sep 4
|
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
|
|
Aug 15
|
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
|
|
Aug 15
|
Cel-Sci: Fiscal Q3 Earnings Snapshot
|
|
Jul 29
|
CEL-SCI Announces Closing of $10.8 Million Offering
|
|
Jul 26
|
CEL-SCI Announces Pricing of $10.8 Million Offering
|
|
Jul 26
|
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
|
|
Jun 18
|
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
|